Interferons as antiangiogenic agents.
Interferons (IFNs), pleiotropic cytokines that regulate antiviral, antitumor, apoptotic, and cellular immune responses, were the first endogenous antiangiogenic regulators identified. In a species-specific manner, IFNs inhibit secretion of such angiogenic factors as basic fibroblast growth factor from tumor cells. The antiangiogenic activity of IFNs is enhanced when they are combined with other antiangiogenic agents, such as tamoxifen and thalidomide.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D007372:Interferons / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D023421:Models, Animal; D012878:Skin Neoplasms / Q000188:drug therapy*; D013629:Tamoxifen / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007376:Interleukin-2; D013629:Tamoxifen; D013792:Thalidomide; D007372:Interferons